| 溶解性 | Soluble in methanol, DMSO (≥15 mg/ml), and ethanol (25 mM). Very poorly soluble in water. Maximum solubility in plain water is estimated to be about 10-50 μM. Buffers, serum, or other additives may increase or decrease the aqueous solubility. |
| 应用 | A c-Abl, Src-Abl, and Bcr-Abl inhibitor |
| 产品介绍 | Bosutinib (SKI-606) is a potent c-Abl, Bcr-Abl, and Src-Abl kinase inhibitor, shown to effectively interfere with the progress of chronic myelogenous leukemia (CML). In a competitive study with Imatinib, Bosutinib was shown to inhibit Bcr-Abl kinase activity in CD34+ CML cells more potently than Imatinib. Activity of Src-Abl has been implicated in the development of other non-CML malignancies, and Bosutinib has demonstrated in studies to suppress breast cancer growth and migration. |
| 合法信息 | Sold for research purposes under agreement from Pfizer Inc. - Not for human or veterinary use. |
| 备注 | Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively. |
| 生化机理 | Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively.Bosutinib (SKI-606) is an orally active; dual Src/Abl tyrosine kinase inhibitor with potent antiproliferative activity. It does not appear to inhibit c-Kit and PDGRF, which are thought to be the cause of numerous side effects in anticancer treatment with some other tyrosine kinase inhibitors. |
| 别名 | 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile;SKI-606;WAY-173606;伯舒替尼;SKI-606;WAY-173606 |
伯舒替尼 (SKI-606)
Bosutinib (SKI-606) （订货以英文为准）
编号：B129905
CAS号：380843-75-4
分子式：C26H29CL2N5O3
分子量：530.45
| 产品名称 | Bosutinib (SKI-606) |
| 中文名称 | 伯舒替尼 (SKI-606) |
| CAS号 | 380843-75-4 |
| 分子式（M.F.） | C26H29CL2N5O3 |
| 分子量（M.W.） | 530.45 |
搜索质检报告(COA)
搜索MSDS
相关产品
¥ 5212.00
2106-0016-1箱
¥ 3406.00
2106-0002 -1箱
¥ 3289.00
2106-0001-1箱
¥ 510.00
P9157-50T-PKG-5T
党沛 
